ATE420179T1 - Identifizierung des plasmodium falciparum erythrozyt membranprotein 1 (pfemp1) gebietes, das adhäsion zum chondroitin sulfat a vermittelt - Google Patents
Identifizierung des plasmodium falciparum erythrozyt membranprotein 1 (pfemp1) gebietes, das adhäsion zum chondroitin sulfat a vermitteltInfo
- Publication number
- ATE420179T1 ATE420179T1 AT00961513T AT00961513T ATE420179T1 AT E420179 T1 ATE420179 T1 AT E420179T1 AT 00961513 T AT00961513 T AT 00961513T AT 00961513 T AT00961513 T AT 00961513T AT E420179 T1 ATE420179 T1 AT E420179T1
- Authority
- AT
- Austria
- Prior art keywords
- chondroitin sulfate
- pfemp1
- identification
- area
- membrane protein
- Prior art date
Links
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 title abstract 2
- 229920001287 Chondroitin sulfate Polymers 0.000 title abstract 2
- 229940059329 chondroitin sulfate Drugs 0.000 title abstract 2
- 108010088113 Plasmodium falciparum erythrocyte membrane protein 1 Proteins 0.000 title 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 210000003743 erythrocyte Anatomy 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
- G01N2333/445—Plasmodium
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15202399P | 1999-09-01 | 1999-09-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE420179T1 true ATE420179T1 (de) | 2009-01-15 |
Family
ID=22541238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00961513T ATE420179T1 (de) | 1999-09-01 | 2000-09-01 | Identifizierung des plasmodium falciparum erythrozyt membranprotein 1 (pfemp1) gebietes, das adhäsion zum chondroitin sulfat a vermittelt |
Country Status (7)
Country | Link |
---|---|
US (1) | US6855323B2 (de) |
EP (1) | EP1212423B1 (de) |
AT (1) | ATE420179T1 (de) |
AU (1) | AU7345500A (de) |
DE (1) | DE60041340D1 (de) |
DK (1) | DK1212423T3 (de) |
WO (1) | WO2001016326A2 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9703386D0 (sv) * | 1997-09-19 | 1997-09-19 | Karolinska Innovations Ab | Malaria polypeptides |
CA2410051A1 (en) * | 2000-05-31 | 2001-12-06 | Institut Pasteur | Proteins involved in cytoadhesion of plasmodium falciparum ring-stage-infected erythrocytes |
WO2002066515A1 (en) * | 2001-02-23 | 2002-08-29 | Institut Pasteur | Generation of monoclonal antibodies to poorly immunogenic antigens expressed or carried by eukaryotic cells, use of monoclonal antibodies for therapeutical, diagnostic or vaccine applications |
AU2003291977A1 (en) | 2003-01-27 | 2004-08-23 | Kobenhavns Universitet | Compounds useful in the diagnosis and treatment of pregnancy-associated malaria |
WO2006039652A2 (en) * | 2004-09-30 | 2006-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chondroitin sulfate a binding domains |
DE602006015985D1 (de) | 2005-09-30 | 2010-09-16 | Philadelphia Health & Educatio | Antigene gegen das leberstadium von plasmodium |
CN102618538B (zh) * | 2011-01-26 | 2015-05-20 | 中国人民解放军第二军医大学 | 一种调控真核生物基因转录的dna序列及其结合蛋白 |
JP6517018B2 (ja) * | 2012-02-09 | 2019-05-22 | ヴァー2・ファーマシューティカルズ・アンパルトセルスカブVAR2 Pharmaceuticals ApS | コンドロイチン硫酸グリカンのターゲティング |
HU230341B1 (hu) | 2012-04-20 | 2016-02-29 | Advancell Diagnosztika Kft. | A vörösvérsejt-membrán kvantitatív biomarkerei |
CN109387627B (zh) * | 2018-10-16 | 2021-09-24 | 中国科学院深圳先进技术研究院 | 一种基于胎盘样硫酸软骨素a的癌症筛查和早期诊断的试剂方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817644A (en) * | 1991-07-03 | 1998-10-06 | Hyal Pharmaceutical Corporation | Targeting of dosages of medicine and therapeutic agents |
US5993827A (en) * | 1993-09-10 | 1999-11-30 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins |
-
2000
- 2000-09-01 DK DK00961513T patent/DK1212423T3/da active
- 2000-09-01 WO PCT/US2000/024195 patent/WO2001016326A2/en active Application Filing
- 2000-09-01 AU AU73455/00A patent/AU7345500A/en not_active Abandoned
- 2000-09-01 DE DE60041340T patent/DE60041340D1/de not_active Expired - Lifetime
- 2000-09-01 AT AT00961513T patent/ATE420179T1/de not_active IP Right Cessation
- 2000-09-01 EP EP00961513A patent/EP1212423B1/de not_active Expired - Lifetime
-
2002
- 2002-02-21 US US10/087,013 patent/US6855323B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2001016326A3 (en) | 2001-08-23 |
WO2001016326A2 (en) | 2001-03-08 |
AU7345500A (en) | 2001-03-26 |
DE60041340D1 (de) | 2009-02-26 |
US6855323B2 (en) | 2005-02-15 |
DK1212423T3 (da) | 2009-04-27 |
EP1212423B1 (de) | 2009-01-07 |
EP1212423A2 (de) | 2002-06-12 |
US20040062769A1 (en) | 2004-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI875082A (fi) | Dna-sekvensser deriverade fraon genom av papillomavirus, deras anvaendning foer in vitro diagnostiska aendamaol; samt framstaellning av antigeniska kompositioner. | |
DE69006018D1 (de) | Impfung und methoden gegen krankheiten, die von pathologischen reaktionen der spezifischen t-zellen abstammen. | |
HK1081598A1 (en) | Treatment of huntington's disease with epa | |
NO963239D0 (no) | Klorpyrimid-mellomprodukter | |
ATE420179T1 (de) | Identifizierung des plasmodium falciparum erythrozyt membranprotein 1 (pfemp1) gebietes, das adhäsion zum chondroitin sulfat a vermittelt | |
FR2703693B1 (fr) | Procédé rapide de détermination d'une séquence d'ADN et application au séquençage et au diagnostic. | |
ATE195149T1 (de) | Protein-antagonisten der blut-koagulation und ihre verwendung | |
WO2003105725A3 (en) | ARTIFICIAL CORNEA | |
WO2004028341A3 (en) | Susceptibility gene for human stroke; methods of treatment | |
WO2002044736A3 (en) | Diagnosis and treatment of epidermal or skin diseases | |
FR2832716B1 (fr) | Proteine de fusion ayant augmente l'activite in vivo de l'erythroproietine | |
ATE519536T1 (de) | Methode zum trennen von zellen | |
WO2001036465A3 (en) | Human zven proteins | |
CA2186423A1 (en) | Protein which induces interferon-gamma production by immunocompetent cell | |
FR2770853B1 (fr) | Gene codant pour la thanatine, vecteur le contenant et plantes transformees obtenues resistantes aux maladies | |
FR2802678B1 (fr) | Systeme et procede d'analyse et de simulation previsionnelle de l'evolution temporelle d'une zone pileuse, et plus particulierement du cuir chevelu humain | |
ATE329638T1 (de) | Vorrichtung, um in einem zielgebiet eines menschlichen oder tierischen körpers einen künstlichen isolierten kreislauf zu etablieren | |
WO2003049683A3 (en) | Use of parapox b2l protein to treat cancer and modify immune responses | |
DE50009932D1 (de) | Gentransfer in humane lymphocyten mittels retroviraler scfv-zelltargeting vektoren | |
TR200003352T2 (tr) | Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler | |
ATE275207T1 (de) | Dna zur abschätzung des progressionspotentials von zervixläsionen | |
MY143222A (en) | Expression vector for animal cell | |
Cabrini et al. | Alternative methods for the assessment of diarrhetic shellfish poisoning risk.] | |
DE3687448D1 (de) | Verwendung von 6h-7,8-dihydrothiapyrano(3,2d)pyrimidinen zur herstellung von arzneimitteln zur verwendung als hypoglykaemische mittel oder als abmagerungsmittel fuer fettsuechtige patienten. | |
UA38258A (uk) | Засіб лікування гіпертонічної хвороби, асоційованої з ішемічною хворобою серця |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |